This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Hannover Medical School, Hannover, Germany

Elmar Jaeckel is a medical doctor in the Department of Gastroenterology, Hepatology & Endocrinology at the Hannover Medical School, Hannover, Germany. He received his training in Hamburg, Germany; Yale New Haven, New Haven, CT, USA; the University of California San Diego, CA, USA; the University of Edinburgh, Edinburgh, UK; and the University of Sydney, Sydney, Australia. Dr Jaeckel spent 4 years as a postdoctoral fellow at the Joslin Diabetes Center of the Harvard Medical School, Boston, MA, USA. He is the attending endocrinologist and diabetologist at the Hannover Medical School.


Dr Jaeckel’s working group, Immune Tolerance, aims to establish immune tolerance in type 1 diabetes and after biological beta-cell replacement. For this purpose, he is developing new cell and gene therapy approaches. Dr Jaeckel is involved in pursuing islet xenotransplantation in Germany. He is also studying non-alcoholic steatohepatitis (NASH) in animal models and patient material and is developing incretin-based therapies for NASH.